Transthyretin amyloid cardiomyopathy (TTC) is a severe cardiovascular disease caused by the accumulation of abnormal amyloid protein transthyretin (TT) in the myocardium. This process leads to myocardial stiffness, impaired cardiac function, and ultimately heart failure. TTC can manifest itself as an inherited form associated with genetic mutations, or as a sporadic form associated with age. The main clinical manifestations are dyspnea, edema, and arrhythmia. The pathogenesis of TTC is associated with metabolic disorders, which leads to myocardial dysfunction and the subsequent development of structural changes in the heart.
History of the disease and interesting historical facts
Transthyretin amyloid cardiomyopathy was first described in 1987, although the amyloid itself had been known for many years earlier. Since its discovery, the disease has attracted the attention of scientists and clinicians due to its diverse clinical manifestations. Interestingly, in 2004, a study on TTC was one of the first to become widely known due to the use of magnetic resonance imaging (MRI) technology. This technology allowed better visualization of structural changes in the myocardium caused by amyloid accumulation. Moreover, in recent years, the number of clinical trials aimed at studying new methods of treating TTC has increased significantly, which emphasizes the relevance of this problem in modern cardiology.
Epidemiology
Epidemiological data show that transthyretin amyloid cardiomyopathy occurs in approximately 10-15% patients with heart failure over the age of 65. The prevalence of TTC varies depending on ethnicity and geographic factors. For example, in some populations, such as Cubans or Scandinavians, cases of the hereditary form of the disease are significantly more common. Men suffer from TTC 3-4 times more often than women, which indicates a possible influence of gender factors on the pathogenesis of the disease.
Genetic predisposition to this disease
Genetic predisposition to transthyretin amyloid cardiomyopathy is mainly associated with mutations in the TTR gene, located on chromosome 18. Research has identified more than 120 different mutations that can lead to different forms of the disease. The most well-known mutations include V30M, which is more common in populations with a hereditary form of the disease, especially in Scandinavia and Japan. Genetic testing can be useful for diagnosis and prognosis in patients with a family history.
Risk factors for the development of this disease
Among the risk factors that contribute to the development of transthyretin amyloid cardiomyopathy, the following are distinguished:
- Age – the disease is more often observed in people over 60 years of age.
- Heredity – having a family history of TTC significantly increases the risk.
- Sexual characteristics – men are at higher risk than women.
- Chronic inflammatory diseases, such as chronic arthritis, may contribute to the development of amyloidosis.
- The co-existence of other diseases, such as diabetes or hypertension, can aggravate the course of the disease.
Diagnosis of this disease
Diagnosis of transthyretin amyloid cardiomyopathy involves evaluation of clinical symptoms and laboratory and radiological examination results. The main symptoms of the disease are:
- Shortness of breath on exertion, which may progress.
- Swelling of the lower extremities.
- Fatigue and decreased physical activity.
- Arrhythmias and cardiac rhythm disorders.
Laboratory tests may include:
- A blood chemistry test that reveals elevated levels of blood natriuretic peptide (BNP).
- Serum transthyretin level test.
- Genetic testing to detect mutations in the TTR gene.
Radiological examinations include:
- Echocardiography, which allows visualization of changes in the structure of the heart.
- Magnetic resonance imaging (MRI) to assess myocardial fibrosis and edema.
- Positron emission tomography (PET) to assess amyloid deposition.
The key stage in diagnostics is the differential diagnosis of TTC with other forms of cardiomyopathy and heart failure, which requires a multidisciplinary approach.
Treatment
Treatment of transthyretin amyloid cardiomyopathy is complex and usually includes pharmacological therapy and, in some cases, surgical intervention. General treatment is aimed at reducing symptoms and improving the quality of life of patients. Pharmacological treatment includes:
- Sertalopram or other antidepressants for millions of patients suffering from depression associated with chronic illnesses.
- Beta blockers and angiotensin-converting enzyme (ACE) inhibitors to control blood pressure and heart failure.
- Drugs that target transthyretin levels, such as patisiren.
In some cases, surgery, including cardiac transplantation, may be required, especially in patients with severe heart failure. In addition, new studies are evaluating promising therapeutic approaches, such as ATP-like inhibitor therapy, which may revolutionize the treatment of TTC.
List of medications used to treat this disease
Among the drugs used to treat transthyretin amyloid cardiomyopathy are:
- Patisiren is an inhibitor that shows promise in combating abnormal accumulation of transthyretin.
- Tefazunib – aims to stabilize transthyretin, preventing its conversion to amyloid.
- Beta blockers – to control heart rhythm and lower blood pressure.
- ACE inhibitors – to relieve the heart in case of heart failure.
- Anticoagulants – in the presence of thrombus formation.
Disease monitoring
Monitoring of a patient with transthyretin amyloid cardiomyopathy involves regular assessment of cardiac function and progression. Control steps may include:
- Regular visits to a cardiologist to assess clinical symptoms.
- Monitoring heart rate and blood pressure.
- Periodic echocardiograms and MRIs to monitor structural changes in the heart.
- Laboratory blood tests to assess transthyretin levels.
The prognosis of the disease depends on the degree of myocardial involvement and the presence of concomitant diseases. Complications may include heart failure, cardiogenic shock, and electrophysiological disorders, which require constant monitoring.
Age-related features of the disease
Transthyretin amyloid cardiomyopathy most often affects people over 60 years of age, but cases of the disease can also occur at a younger age in patients with genetic mutations. In older people, the disease is characterized by more pronounced symptoms and a more rapidly progressing course. In younger patients, symptoms may be less pronounced, and even latent forms of the disease may be observed, which requires careful diagnosis and monitoring.
Questions and Answers
- What is transthyretin amyloid cardiomyopathy? TTC is a disease caused by the accumulation of the amyloid protein transthyretin in the heart tissue, which leads to impaired heart function.
- What are the main symptoms of TTC? The main symptoms include shortness of breath, swelling, arrhythmia and fatigue.
- What risk factors may contribute to the development of TTC? Major risk factors include age, heredity, gender and the presence of chronic diseases.
- How is TTC diagnosed? Diagnosis is based on clinical manifestations, laboratory and radiological tests, including echocardiography and genetic testing.
- What are the current approaches to treating TTC? Treatment includes drug therapy such as transthyretin inhibitors, and in some cases surgery may also be possible.
